Summary: Twenty-four-hour urine specimens from 21 juvenile insulin-dependent diabetics and 10 healthy controls were compared with respect to biotinidase activity and alanine content. Urinary biotinidase activity was analysed by a newly developed high-performance liquid chromatography (HPLC) method. It was found that the excretion of biotinidase in urine was elevated in diabetics (7.02 mU/d; p < 0.005) as compared with controls (not detectable). Alanine excretion was also found to increase (p < 0.01) in diabetics. Biotinidase excretion in diabetics was correlated with alanine excretion (rS = 0.667; p < 0.01), but not with protein, albumin or N-acetyl--glucosaminidase excretion. The simultaneous elevation of urinary biotinidase and alanine excretion in juvenile diabetics suggests that changes in kidney metabolism arise in the early stages of diabetes.
Introduction
Diabetic nephropathy develops particularly often among patients with juvenile onset diabetes mellitus, in which the cumulative risk of nephropathy is about 30-40%.
Morphological changes in the capillary basement membrane and microalbuminuria are readily detectable in the kidney of early diabetic nephropathy patients (1-3). The current chemical standard for detecting nephropathy is micro-albuminuria (4) . Decreased contents of cystine and sialic acid have been reported in diabetic kidney (5) . Changes in the renal handling of some amino acids in diabetic kidney have also been suggested (6) .
Biotinidase (EC 3.5.1.12), an amidase that hydrolyses biocytin, is present in the microsome fraction (endoplasmic reticulum) of guinea pig and rat livers (7, 8) , and the activity of this enzyme in pig and rat has been shown to be highest in the kidneys (8) (9) (10) . This enzyme from human serum also recognizes lipoyl-amide compounds (11, 12) and enkephalin (13) . From studies on biotinidase deficiency (14) , it has been suggested that one of the major biological roles of biotinidase is to recycle biotin. Studies on patients with biotinidase deficiency (15) also indicate that kidney biotinidase functions in the re-uptake of biotin and biocytin. Elevated alanine levels in urine of biotinidase deficient patients have also been recently reported (16) . Biotinidase has been shown to be detectable in various renal diseases (17) . Therefore, ') A part of this work was presented at the 20th annual meeting of the international society for pediatric and adolescent diabetes, Atami-city, Shizuoka, Japan, November, 1994.
we compared biotinidase and alanine excretion in the urine of diabetics and controls in order to clarify the role of biotinidase in the kidney.
Materials and Methods

Patients
Patients (n = 21, female n = 12, male n = 9) with juvenile onset diabetes mellitus: 17 outpatient and 4 hospitalized cases from the National Children's Hospital (Tokyo, Japan).
Clinical profiles in 21 patients with insulin-dependent diabetes mellitus: Age, 13.0 years (median), 3-26 years (range); Duration of insulin-dependent diabetes mellitus, 5.0 years (median), 0-22 years (range); Blood pressure, systolic 14.5 ±2. 13 All of the diabetic group received a diabetic diet and insulin, produced in USA (Lilly) and Denmark (Novo Nordisk). Insulin was injected 2-4 times per day but one of the hospitalized patients received pump insulin injection. In addition, one diabetic patient was treated with steroid and another with thyroxin for to concomitant diseases. Preproliferative diabetic retinopathy was marked in 3 patients, 1 had transitional proteinuria with 22 years of duration, 1 had bulimia. Concomitant diseases: nephrosis, one patient; thyroid disturbance, one patient; hand abnormality, one patient; Down's syndrome, one patient.
Healthy controls
Healthy volunteers (n = 10; female 4, male 6) of the institute. All the volunteers were free from anomalies or pathology of kidneys, urinary tract infection, and other acute infections. Characteristics of healthy controls: Age, 12.0 years (median), 7-50 years (range); volume of urine, 0.885 1 (median), 0.624-2.9611 (range). USA). Filtered urine samples were diluted 40-fold with 0.1 mol/1 HC1, and a 0.01 ml portion was injected into the HPLC system.
Specimens
Twenty-four-hour urine samples were collected from diabetic patients. After measuring the total volume, an aliquot was filtered (Ekicrodisc 13; 200 nm pore size Versapor, Gelman Sciences Japan, Ltd., Tokyo, Japan) and stored at -80 °C.
Chemicals and reagents
Biotinyl-6-aminoquinoline and biocytin were purchased from Sigma Chemical Co., St. Louis, MO, USA. 6-Aminoquinoline was from Aldrich Chemical Co., Milwaukee, WI, USA. L-Amino acid standards were from Takara Kohsan Co., Ltd., Tokyo, Japan. Polyoxyethylene (20) cetyl ether (Brij-58), glycerol, o-phthalaldehyde and l,2-diamino-4,5-methylenedioxybenzene dihydrochloride were from Wako Pure Chemical Co., Osaka, Japan. Sialic acid (N-acetylneuraminic acid) was from Nacalai Tesque, Inc., Kyoto, Japan. Develosil ODS-10 (octadecylsilane-bonded silica gel for high-performance liquid chromatography) was from Nomura Chemical Co., Seto, Aichi, Japan.
Miscellaneous urine analyses
Free and total sialic acid was measured by an HPLC-fluorimetric method (21) . N-Acetyl--glucosaminidase activity was measured in 12 samples out of 21 patient urines by a photometric method using 6-methyl-2-pyridyl-N-acetyl--glucosamine as substrate (Nittobo Medical Co., Tokyo, Japan). C-peptide was measured in 20 samples out of 21 patient urines by a RIA method (using samples stored at -80°C).
Statistical analysis
Non-parametric statistical analysis was performed. Mann-Whitney's U test was used for assessing the significance of the difference of two groups. Spearman's rank correlation coefficients (rS) were used for estimating correlations between two groups. Calculations were performed on a personal computer (Epson PC-485GR Super, Seiko-Epson Co., Suwa-City, Nagano 392, Japan), using the software: Statflex Lite, Version 2 (J. I. P. Co., Tokyo, Japan). A probability value below 0.01 was considered to be significant.
Biotinidase
Biotinidase activity in urine was measured by the high-performance liquid chromatography (HPLC) fluorometric method (17) using biotinyl-6-aminoquinoline as substrate. Biotinyl-6-aminoquinoline was dissolved at 0.044 mmol/1 (16.3 mg/1) in 0.1 mol/1 sodium phosphate buffer (pH 7.0) containing 1 mmol/1 (452 mg/1) Na-EDTA and 10 mmol/1 (781 mg/1) 2-mercaptoethanol. Substrate in 0.090 ml of the reaction buffer was mixed with 0.010 ml of enzyme solution. Thus, the reaction mixture (0.100 ml) contained 1.468 μg (3.96 nmol) of biotinyl-6-amino-qumoline, 0.040 mg of EDTA and 0.070 mg of 2-mercaptoethanol. The reaction was allowed to proceed for an appropriate time at 37 °C, then stopped by adding 0.200 ml of methanol; the reaction mixture was diluted three-fold with methanol to precipitate the enzyme proteins. After centrifugation and deproteinization at 1500 g for 15 min, a portion (0.010 ml) of the clear supernatant was injected into the HPLC system. The HPLC system for biotinidase assay consisted of a model 600E HPLC pump (Waters Associates, Inc., Milford, MA, USA), an injector (model U6K), a reversed-phase column (octadecylsilane bonded silica gel; 10 μπι sphere; 50 X 4.0 mm I. D.), and a detector (model F-3000 fluorescence spectrophotometer, Hitachi, Tokyo, Japan). The product 6-aminoquinoline was separated by the reversed-phase column, and measured at an excitation wavelength of 350 nm and an emission wavelength of 550 cm. The rate of release of 6-aminoquinoline from substrate was calculated as previously described (17) .
Biotinidase activity was also determined by measuring the release of Ζ,-lysine from biocytin (0.152 mmol/1), using an HPLC amino acid analyser according to the method described previously (13).
An enzyme unit was defined according to Ochoa et al. (18) , i.e. one unit was the amount of enzyme catalysing the release of 1 nmol of 6-aminoquinoline per minute at 37 °C from biotinyl-6-aminoquinoline or 1 nmol of lysine from biocytin. Specific activity was expressed as units per mg of (urinary) protein. The values were multiplied by 1000 in order to obtain International Units (l U = 1 μιηοΐ/min).
Urinary proteins and albumin determinations
Proteins and albumin in the urine were determined by sensitive high-performance gel-permeation chromatography as described previously (19) .
Free amino acid measurements
Free L-amino acids were measured by using an HPLC amino-acid analyser (Na + -type) as described previously (20) 
Results and Discussion
It was found that 67% (14/21) of patients showed positive or pathological biotinidase excretion as compared to a control level of 10% (1/10); i.e., the cut-off level for negativity was defined as 90% of controls ( fig. 1 ).
As shown in table 1, this elevation was found to be significant (p < 0.005) as estimated by Mann-Whitney's U test. There were no statistically significant differences between the controls and patients with respect to age and sex, according to Mann-Whitney's U test for age and Fisher's exact test for sexes, respectively.
As also shown in figure 2 and table 1, only alanine and valine excretion were significantly (p < 0.01) increased in diabetic urine. Other amino acids and analytes, such as free sialic acid, total proteins, and albumin were not significantly elevated.
Urinary biotinidase and albumin have similar molecular masses and different characteristics, which are summarized in table 2. Although biotinidase and albumin have similar acidic pi values, their excretion showed no correlation at all (tab. 3). Biotinidase excretion showed a positive correlation (rS = 0.667; p < 0.01) with alanine excretion (tab. 3). Thus, the urines of insulin-dependent diabetes mellitus patients show simultaneous elevations of biotinidase and alanine excretion, which are positively correlated. In the control group, biotinidase excretion (n = 3) was not correlated with alanine excretion.
Normal energy metabolism, as determined by the production and utilization of ATP and NADH, is known to be essential for kidney preservation and transplantation (22, 23) . It is also known that kidney is the tissue containing the highest biotinidase activity in pig (9). Baumgartner et al. (15) have suggested that kidney biotinidase functions in the reabsorption of biotin and biocytin. The active transport of L-alanine in bacteria has been demonstrated using NADH or ascorbate plus phenazine methosulphate as energy sources (24) . Therefore, kidney biotinidase and the alanine transport system may be linked through the energy metabolism of the kidney. elevation of biotinidase and alanine is rare. To determine whether the simultaneous elevation of biotinidase and alanine excretion is possibly the earliest detectable manifestation of a predisposition to diabetic nephropathy, we re-inspected our urinary data of 21 insulin-dependent diabetes mellitus patients. It was found that 8 out of 21 patients (38%) showed elevated excretion of both biotinidase and alanine. This value of 38% is similar to the cumulative risk of nephropathy (30-40%).
Since preliminary studies suggest that early morning urine is as suitable as 24-hour urine for these studies, monitoring of these eight patients is expected to continue.
